StockNews.com Initiates Coverage on Akari Therapeutics (NASDAQ:AKTX)

StockNews.com started coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a research note issued to investors on Wednesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Akari Therapeutics Stock Down 1.7 %

NASDAQ:AKTX opened at $1.19 on Wednesday. The company has a 50 day moving average price of $1.82 and a 200-day moving average price of $2.63. Akari Therapeutics has a 1-year low of $1.08 and a 1-year high of $5.50.

Institutional Investors Weigh In On Akari Therapeutics

An institutional investor recently raised its position in Akari Therapeutics stock. Omnia Family Wealth LLC increased its stake in Akari Therapeutics, Plc (NASDAQ:AKTX) by 48.2% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 87,628 shares of the biopharmaceutical company’s stock after acquiring an additional 28,511 shares during the quarter. Omnia Family Wealth LLC owned approximately 1.55% of Akari Therapeutics worth $273,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 5.06% of the company’s stock.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.